The impact of recent power morcellator risk information on inpatient surgery and patient outcomes
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: We examine the impact of the new risk information about a surgical device on surgery and patient outcomes for hysterectomy in the inpatient setting. Methods: We utilize a difference-in-differences approach to assess the impact of new risk information on patient outcomes in the inpatient setting between 2009 and 2014. The inpatient data come from a nationally representative sample of hospitalizations in the USA. We use the likelihood of laparoscopic surgery, measures of resource use and surgical complications as outcome variables. Results: We estimate a three-percentage point decrease in the likelihood of receiving laparoscopic hysterectomy, a one-percentage point increase in the likelihood of experiencing a surgical complication and no impact on resource use, relative to pre-existing means. Conclusion: Our findings show that there was movement away from laparoscopic surgery in the months following the dissemination of new risk information. These changes had limited effect on patient outcomes.
Supplementary Material
File (suppl_file.docx)
- Download
- 252.94 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in Black and White Women: ultrasound evidence. Am. J. Obstet. Gynecol. 188, 100–107 (2003).
2.
Cain-Nielsen AH, Moriarty JP, Stewart EA, Borah BJ. Cost–effectiveness of uterine-preserving procedures for the treatment of uterine fibroid symptoms in the United States. J. Comp. Eff. Res. 3, 503–514 (2014).
3.
Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am. J. Obstet. Gynecol. 206, 211.e211–211.e219 (2012).
4.
NIH. Uterine fibroids. NIH fact sheets (2010). https://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=50
5.
Kashani BN, Centini G, Morelli SS, Weiss G, Petraglia F. Role of medical management for uterine leiomyomas. Best Pract. Res. Clin. Obstet. Gynaecol. 34, 85–103 (2016).
6.
The American College of Obstetricians and Gynecologists. Uterine fibroids FAQ074 (2011). https://www.acog.org/~/media/For%20Patients/faq074.pdf?dmc=1.
7.
Wright JD, Chen L, Burke WM et al. Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation. JAMA 316, 877–878 (2016).
8.
Food and Drug Administration. Laparscopic power morcellators (2018). https://www.fda.gov/medical-devices/surgery-devices/laparoscopic-power-morcellators.
9.
Ebner F, Friedl TWP, Scholz C et al. Is open surgery the solution to avoid morcellation of uterine sarcomas? A systematic literature review on the effect of tumor morcellation and surgical techniques. Arch. Gynecol. Obstet. 292, 499–506 (2015).
10.
American Cancer Society. What is uterine sarcoma? (2019). https://www.cancer.org/cancer/uterine-sarcoma/about/what-is-uterine-sarcoma.html.
11.
Peters A, Sadecky AM, Winger DG et al. Characterization and preoperative risk analysis of leiomyosarcomas at a high-volume tertiary care center. Int. J. Gynecol. Cancer 27(6), 1183–1190 (2017).
12.
Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS ONE 7, e50058 (2012).
• One of the early studies reporting the risk of malignancy occurring with a diagnosis for benign uterine fibroids was one in 10,000.
13.
The United States Food and Drug Administration. FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids (2017). https://www.fda.gov/media/109018/download
14.
American College of Obstetricians and Gynecologists. Uterine morcellation for presumed leiomyomas. ACOG Committee Opinion Number 770. Obstetr. Gynecol. 133, e238–e248 (2019).
15.
Hartmann KE, Fonnesbeck C, Surawicz T et al. Management of uterine fibroids. Comparative Effectiveness Review Number 195 (AHRQ Publication No. 17(18)-EHC028-EF), (2017).
16.
Bojahr B, Dewilde RL, Tchartchian G. Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH). Arch. Gynecol. Obstet. 292, 665–672 (2015).
17.
Pritts EA, Vanness DJ, Berek JS et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol. Surg. 12, 165–177 (2015).
18.
Kho KA, Lin K, Hechanova M, Richardson DL. Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. Obstet. Gynecol. 127, 468–473 (2016).
19.
Desai VB, Wright JD, Gross CP et al. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectormy. Am. J. Obstet. Gynecol. 39.e31–39.e14 (2019).
20.
Levitz J. Doctors eye cancer risk in uterine procedure. The Wall Street Journal (2013). https://www.wsj.com/articles/doctors-eye-cancer-risk-in-uterine-procedure-1387328455
• This newspaper article was one of the first ones in the media raising awareness regarding the risk of morcellation.
21.
Levitz J. Fibroid surgery puts doctor fighting cancer diagnosis in spotlight. The Wall Street Journal (2013). https://www.wsj.com/articles/fibroid-surgery-puts-doctor-fighting-cancer-diagnosis-in-spotlight-1387457121
22.
The United States Food and Drug Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication (2014). https://wayback.archive-it.org/7993/20170406071822/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576.htm
23.
The United States Food and Drug Administration. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids (2014). https://www.fda.gov/media/88703/download
• This is FDA's Safety Communication warning against the use of laparoscopic power morcellation in the removal of uterine fibroids.
24.
The United States Food and Drug Administration. Updated laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication (2014). https://wayback.archive-it.org/7993/20170404182209/https:/www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm
25.
The United States Food and Drug Administration. Immediately in effect guidance document: product labeling for laparoscopic power morcellators. guidance for industry and food and drug administration staff (2014). https://www.fda.gov/media/90012/download
26.
Kamp J, Levitz J. Johnson & Johnson Pulls hysterectomy device from hospitals. The Wall Street Journal (2014). https://www.wsj.com/articles/johnson-johnson-to-call-for-voluntary-return-of-morcellators-1406754350
27.
Kamp J. Hospital chain HCA prohibits power morcellation for uterine fibroids. The Wall Street Journal (2014). https://www.wsj.com/articles/hospital-chain-hca-prohibits-power-morcellation-for-uterine-fibroids-1416948061
28.
Kamp J, Levitz J. Philadelphia hospital restricts ‘morcellation’ procedure. The Wall Street Journal (2014). https://www.wsj.com/articles/no-headline-available-1392904045
29.
Kamp J. More health insurers take action to curb morcellator use. The Wall Street Journal (2015). https://www.wsj.com/articles/more-health-insurers-take-action-to-limit-morcellator-use-1428009386
30.
Kamp J. Aetna to stop covering routine use of power morcellator. The Wall Street Journal (2015). https://www.wsj.com/articles/aetna-to-stop-covering-routine-use-of-power-morcellator-1430838666
31.
Levitz J, Kamp J. Biggest U.S. Health insurer tightens rules on hysterectomy coverage. The Wall Street Journal (2015). https://www.wsj.com/articles/biggest-u-s-health-insurer-tightens-rules-on-hysterectomy-coverage-1424990877
32.
Barron KI, Richard T, Robinson PS, Lamvu G. Association of the U.S. Food and Drug Administration morcellation warning with rates of minimally invasive hysterectomy and myomectomy. Obstet. Gynecol. 126, 1174–1180 (2015).
• This study found a decrease in the proportion of minimally invasive hysterectomies and myomectomies performed during the 8 months after the FDA safety communication on the use of power morcellation.
33.
Harris JA, Swenson CW, Uppal S et al. Practice Patterns and postoperative complications before and After US Food and Drug Administration Safety communication on power morcellation. Am. J. Obstet. Gynecol. 214, 98e91–98e13 (2016).
34.
Multinu F, Casarin J, Hanson KT et al. Practice patterns and complications of benign hysterectomy following the FDA statement Warning against the use of power morcellation. JAMA Surg. 153, e180141 (2018).
• This study reported that utilization of minimally invasive hysterectomy decreased, and major surgical complications and 30-day hospital re-admissions increased after the April 2014 FDA safety communication.
35.
Ottarsdottir H, Cohen SL, Cox M, Vitonis A, Einarsson JI. Trends in mode of hysterectomy after the U.S. Food and Drug Administration power morcellation advisory. Obstet. Gynecol. 129, 1014–1021 (2017).
36.
Schoenman JA, Sutton JP, Kintala S, Love D, Maw R. The Value of Hospital Discharge Databases. (AHRQ Contract number 282-98-0024 [Task Order Number 5]) (2005). https://www.hcup-us.ahrq.gov/reports/final_report.pdf
37.
Piedimonte S, Czuzoj-Shulman N, Gotlieb W, Abenhaim HA. Robotic Radical hysterectomy for cervical cancer: a population-based study of adoption and immediate postoperative outcomes in the United States. J. Minim. Invasive Gynecol. 26(3), 551–557 (2019).
38.
Desai VB, Guo XM, Fan L, Wright JD, Xu X. Inpatient laparoscopic hysterectomy in the United States: trends and factors associated with approach selection. J. Minim. Invasive Gynecol. 24, 151–158 (2017).
39.
Wright JD, Herzog TJ, Tsui J et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 122, 233–241 (2013).
40.
Lee J, Jennings K, Borahay MA et al. Trends in the national distribution of laparoscopic hysterectomies from 2003–2010. J. Minim. Invasive Gynecol. 21, 656–661 (2014).
41.
Rosero EB, Kho KA, Joshi GP, Giesecke M, Schaffer JI. Comparison of robotic and laparoscopic hysterectomy for benign gynecologic disease. Obstet. Gynecol. 122(4), 778–786 (2013).
42.
Mannschreck D, Matsuno RK, Moriarty JP et al. Disparities in surgical care among women with endometrial cancer. Obstet. Gynecol. 128(3), 526–534 (2016).
43.
Jacoby VL, Autry M, Jacobson G, Domush R, Nakagawa S, Jacoby A. Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet. Gynecol. 114(5), 1041–1048 (2009).
44.
Lowder JL, Oliphant SS, Ghetti C, Burrows LJ, Meyn LA, Balk J. Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979–2004. American Journal of Obstetrics & Gynecology 202, 538.e531–538.e539 (2010).
45.
Kolstad JT, Kowalski AE. The impact of health care reform on hospital and preventive care: evidence from Massachusetts. J. Public Econ. (96), 909–929 (2012).
46.
Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373–383 (1987).
47.
Stagg V. Charlson: Stata Module to Calculate Charlson Index of Comorbidity. Statistical Software Components S456719 (2006). https://ideas.repec.org/c/boc/bocode/s456719.html
48.
Nexhat F, Apostol R, Greene AD, Pilkinton ML. To morcellate or not to morcellate: a cross-sectional survey of gynecologic surgeons. JSLS 21(1), e2016.00092 (2017).
49.
Lum DA, Sokol ER, Berek JS et al. Impact of the 2014 Food and Drug Administration warnings against power morcellation. J. Minim. Invasive Gynecol. 23, 548–556 (2016).
•• Concludes that most members of American College of Obstetricians and Gynecologists Collaborative Ambulatory Research (ACOG CARN) and the Advancing Minimally Invasive Gynecologic Surgery Worldwide (AAGL) who were surveyed believe that the 2014 FDA warnings have not improved patient outcomes.
50.
Graebe K, Garcia-Soto A, Aziz M et al. Incident power morcellation of malignancy: a retrospective cohort study. Gynecol. Oncol. 136, 274–277 (2015).
51.
Taylan E, Sahin C, Zeybek B, Akdemir A. Contained morcellation: review of current methods and future directions. Front. Surg. 4 (Article 15), (2017).
52.
American Cancer Society. Survival rates for uterine sarcoma (2019). https://www.cancer.org/cancer/uterine-sarcoma/detection-diagnosis-staging/survival-rates.html.
53.
The United States Department of Health and Human Services. Guidelines for regulatory impact analysis: a primer. Office of the assistant secretary for planning and evaluation, 2016 (2016). https://aspe.hhs.gov/system/files/pdf/242931/HHS_RIAGuidancePrimer.pdf
54.
Guest JF, Sladkevicius E, Gough N, Linch M, Grimer R. Utility values for advanced soft tissue sarcoma health states from the general public in the United Kingdom. Sarcoma 2013, 9 (2013).
55.
Felix JC, Lacey MJ, Miller JD, Lenhart GM, Spitzer M, Kulkarni R. The clinical and economic benefits of co-testing versus primary HPV testing for cervical cancer screening: a modeling analysis. J. Women's Health 25, 606–616 (2016).
56.
Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of a nationally representative values for the noninstitutionalized US adult population for 7 health-related quality of life scores. Med. Decis. Making 26(4), 391–400 (2006).
57.
Miller JD, Lenhart GM, Bonafede MM, Lukes AS, Laughlin-Tommaso SK. Cost–effectiveness of global endometrial ablation vs hysterectomy for treatment of abnormal uterine bleeding: US commercial and medicaid payer perspectives. Popul. Health Manag. 18, 373–382 (2015).
58.
Fitch K, Huh W, Bochner A. Open vs minimally invasive hysterectomy: commercially insured costs and readmissions. Manag. Care 25(8), 40–47 (2016).
59.
Jorgensen EM, Modest AM, Hur H-C, Hacker MR, Awtrey CS. Hysterectomy practice patterns int he postmorcellation Era. Obstet. Gynecol. 133(4), 643–649 (2019).
60.
Doll KM, Busetzina SB, Robinson W. Trends in inpatient and outpatient hysterectomy and oophorectomy among commercially insured women in the United States: 2000–2014. JAMA Surg. 151, 876–877 (2016).
61.
Moore BJ, Steiner CA, Davis PH, Stocks C, Barrett ML. Trends in hysterectomies and oophorectomies in hospital inpatient and ambulatory settings, 2005–2013. HCUP Statistical Brief #214 (2016). https://www.ncbi.nlm.nih.gov/books/NBK409175/
62.
Wier LM, Steiner CA, Owens PL. Surgeries in hospital-owned outpatient facilities, 2012. HCUP Statistical Brief#188. February 2015 (2012).
63.
Clark NM, Schembri M, Jacoby VL. Change in surgical practice for women with leiomyomas after the U.S. food and drug administration morcellator safety communication. Obstet. Gynecol. 130, 1057–1063 (2017).
64.
The United States Food and Drug Administration. Urogynecologic surgical mesh implants, April 16, 2019 (2019). https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-womens-health-orders-manufacturers-surgical-mesh-intended-transvaginal
65.
The United States Food and Drug Administration. FDA statement. Statement from FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., and Jeff Shuren, M.D., J.D., Director of the FDA's Center for Devices and Radiological Heath on FDA's New Efforts to Protect Women's Health and Help to Ensure the Safety of Breast Implants, May 2, 2019 (2019). https://www.fda.gov/news-events/press-announcements/statement-fda-principal-deputy-commissioner-amy-abernethy-md-phd-and-jeff-shuren-md-jd-director-fdas
Information & Authors
Information
Published In
Pages: 53 - 65
PubMed: 31840551
Copyright
© 2019 Future Medicine Ltd.
History
Received: 11 July 2019
Accepted: 18 October 2019
Published online: 16 December 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
The impact of recent power morcellator risk information on inpatient surgery and patient outcomes. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0093
Export citation
Select the citation format you wish to export for this article or chapter.